Polyrizon Ltd. Ordinary Shares
PLRZPolyrizon Ltd. is a biotechnology company specializing in the development of advanced antimicrobial and anti-viral solutions. The company focuses on innovative technologies aimed at enhancing hygiene and preventing the spread of infectious diseases. Through its research and development efforts, Polyrizon aims to create effective, safe, and sustainable health products for various applications.
Company News
Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company, announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC. The company specializes in developing intranasal protective solutions using proprietary hydrogel technology delivered as nasal sprays to create a barrier again...
Polyrizon successfully completed a pre-submission meeting with the FDA regarding its PL-14 Allergy Blocker nasal spray, discussing development plans, manufacturing, and clinical trial strategies for a potential product targeting the growing global allergen blocker market.
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.
Polyrizon, a biotech company, has initiated preclinical studies for intranasal Naloxone, a treatment for opioid overdose, using its Trap and Target (T&T) platform. The studies aim to assess key parameters like drug loading, release kinetics, and nasal deposition, paving the way for further safety and efficacy testing.
Polyrizon, a biotech company, announced the filing of a divisional patent application for its Trap & Target (T&T) intranasal drug delivery platform. The T&T platform aims to enhance the effectiveness of medications by increasing their residence time and bioavailability.
